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S1 - Immunotherapy in bladder cancer
 Borislav Belev
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia
Immunotherapy presents a completely new approach in systemic treatment in oncology, recognized 
also in genitourinary tumors and bladder cancer as well. In contrast to renal cancer, where we have some 
therapuetic options of systemic treatment for some time and thus more or less known sequence of treat-
ment lines, for metastatic bladder cancer we had very few treatment options. For several decades they are 
based on chemotherapy-protocols (so called MVAC-protocol or cysplatina and gemcitabin-combination), 
but with no further standard lines of treatment. Except much less toxicity, immunotherapy showed sur-
prisingly high activity, which we haven’t seen for last 30 years. The basic concept of this kind of systemic 
treatment is founded on interaction between PD-molecule (PD=programmed death) expressed on host 
(immune) cells and PD-L1 (ligand for PD), produced by tumor and immune cells, as well. Abntibodies 
which we examined as therapy, bind on the PD-molecule or PD-L1 molecule thus disturbing their interac-
tion. Among new antibodies, there is atezolizumab (IgG1 anti-PD-L1 monoclonal antibody), tested in clini-
cal study phase II, known as Imvigor, which included 429 patients, previously treated (N=310) or untreated 
(N=129) by chemotherapy based on chemotherapy. Objective response was 15%, and 26% in those with 
tumors infi ltrating 5% of PDL-1 expressing cells (N=100). US FDA (Food and Drug Administration) has 
granted atezolizumab accelerated approval in May 2016 for fi rst line treatment of metastatic urothelial 
cancer, as a fi rst anti-PD-L1 immunotherapy. Phase III study is on going. The drug is applied in dose of 
1200 mg intravenously, q3w during 60 min infusion until progression of disease or unacceptable toxicity. 
The are also very encouraging results with other agents, like pembrolizumab, showing similar response of 
25% (7/28). In phase III clinical study (KEYNOTE-045), pembrolizumab was compared to chemotherapy, 
given up to 24 months, and overall survival was superior in immunotherapy arm (10.3 vs 7.4 months, 
p=0.0022). Avelumab is next agent (IgG1 anti-PD-L1 antibody, completely by mechanism of antibody-
dependent cell citotoxicity), with overall response of about 18% (8/44). These results led to further clinical 
trials with PD-1/PD-L1-targeted agents, either in combination or as monotherapy. Nivolumab was granted 
approval by US FDA in February 2017, as additional PD-L1 inhibitor in treatment of urothelial cancer. 
Nivolumab is given 240 mg intravenously in 60 minutes-infusion, every 2 weeks, until disease progression 
or unacceptable toxicity. In phase II single-arm clinical trial (Checkmate-275), there were 270 patients
Nivolumab was studied in phase II study (Checkmate-275), with 270 patients, with overall response 
of 19.6%, 23% of patients had stable disease. In conclusion, we still do not have clear criteria for patients 
expecting to have benefi t from immunotherapy. Nevertheless, a portion of patients showing good response 
in urological malignancies is mostly comparable to results obtained from other primary tumors treated 
with immunotherapy (about 20%). Thus, this promising treatment is recommendable for only part of our 
patients.
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S2 - Therapeutic options in treatment of hormonal resistant breast cancer
 Simona Borštnar
Institute of Oncology, Ljubljana , Slovenia
Approximately 70% of breast cancers (BC) may be considered hormone responsive due to expression 
of estrogene and/or progesterone receptors (ER and PR). Hormonal therapy (HT) is a standard treatment 
option for hormonal receptor positive (HR+) BC in all disease stages. HT include nonsteroidal and steroi-
dal aromatase inhibitors (AI), selective ER modulators (tamoxifen), ER down regulators (fulvestrant), pro-
gestin as well as androgens, and high-dose estrogen.
Despite standard adjuvant hormonal therapy, approximately 20–30% of patients with HR+ BC will 
suﬀ er recurrences and the development of metastatic disease. It is estimated that ~30% of patients with 
metastatic BC regress with initial HT and another 20% have prolonged stable disease. Response duration 
to subsequent therapies correspondingly decreases, and all patients with metastatic disease ultimately 
become resistant to HT.
De novo or acquired resistance to HT remains an important therapeutic challenge. Resistance to HT in 
HR+ breast cancer is associated with diverse molecular mechanisms, including acquired mutations in ER-
alpha, cross talk between ER and growth factor receptor signalling such as PI3K/Akt/mTOR pathway, 
HER family members and fi broblast growth factor receptor (FGFR) pathways, constitutive activation of 
cyclin-dependent kinases (CDK) 4 and 6 as well as epigenetic modifi cations by histone deacetylase (HDAC) 
and interactions with tumor microenvironment and host immune response.
Increased understanding of hormonal resistance mechanisms has led to the development of targeted 
agents that overcome resistance and enhance the eﬃ  cacy of HT. The several clinical trials showed that 
addition of a targeted therapy to HT versus HT alone allows prolongation of progression-free survival 
(PFS) in HR+, HER2 negative BC. Based of such clinical trials two agents are currently approved by Euro-
pean Medicines Agency (EMA), including the mTOR inhibitor everolimus and the CDK 4/6 inhibitor pal-
bociclib.
PI3K/AKT/mTOR is the most commonly altered pathway in HR+ BC, and there are a number of 
agents targeting this specifi c pathway. In clinical trial BOLERO 2 combination of mTOR inhibitor everoli-
mus and a steroidal AI exemestane was compared with examestane alone and showed the doubling of the 
PFS, however prolongation of survival was not statistically signifi cant.
CDK 4 and 6 interacts with cyclin D1 in an active protein complex, that promotes cell proliferation. 
There is a strong link between the actions of estrogen and CDK4/6 activity. Therefore, CDK 4/6 represent 
potential therapeutic targets for HR+ breast cancer. Inhibition of the CDK 4/6 pathways is possible by 
small molecule inhibitor drugs such as palbociclib, ribociclib, and abemaciclib. Palbociclib was the fi rst 
and at that time only anti-CDK 4/6 drug approved by EMA based on the PALOMA 2 and 3 clinical trials, 
which showed that addition of palbociclib either to letrozole in fi rst line or fulvestrant in second line 
doubled PFS compared to HT alone.
Other targeted therapies next to mTOR inhibitors and CDK4/6 inhibitors that are being actively inves-
tigated in the clinic include, PI3K inhibitors (buparlisib, alpelisib, and taselisib), HDAC inhibitors (entino-
stat), FGFR inhibitors (dovitinib and lucitinib), and others.
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S3 - Future treatment of triple-negative breast cancer
 Natalija Dedić Plavetić
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, School of Medicine, 
University of Zagreb, Croatia
Breast cancer is the most commonly diagnosed cancer in female population worldwide. Advances in 
understanding tumor biology, particularly signaling pathways, have led to the development and approval 
of novel therapeutic agents, especially in HER2 positive and hormone receptor positive subtypes. Triple-
negative breast cancer (TNBC) is defi ned by lack of expression of estrogen receptor, progesteron receptor 
and HER-2 amplifi cation and accounts for approximately 15-20% of breast cancers. It is also a heteroge-
neous group of tumors which tend to have an aggressive phenotype with higher recurrence rates and 
lower survival rates. This subtype lacks unifying molecular alterations that can guide therapy decisions.
To date, there are no approved targeted therapies specifi cally for this subtype; however, many are in 
development. The most important future strategies will be those for targeting triple-negative breast can-
cers through novel receptors, harnessing the immune system, and new ways of targeting angiogenesis.
Ongoing research is investigating targetable novel cell surface receptors, the use checkpoint inhibi-
tors, and identifying subgroups likely to benefi t from platinum-based therapies and poly(adenosine 
diphosphate-ribose) polymerase inhibitors. The androgen receptor (AR) has been identifi ed as a possible 
predictive biomarker for antiandrogen therapy in ER- breast cancer. AR positivity has been associated 
with more favorable prognoses in TNBC. There are several studies that show AR is associated with lower 
Ki-67 proliferative marker, lower mitotic score, lower histologic grade and lower clinical stage.
Since the presence of residual disease after completion of neoadjuvant therapy predicts poor progno-
sis, numerous clinical trials are designed to test the value of further adjuvant therapy in TNBC patients 
with residual disease. Preliminary results of the CREATE-X (JBCRG-04) trial by the Japan Breast Cancer 
Research Group were presented at the 2015 San Antonio Breast Cancer Symposium. Two ongoing US 
studies examine the value of more chemotherapy or immunotherapy as adjuvant treatment for patients 
with residual TNBC after neoadjuvant chemotherapy.
While numerous studies investigating anti–vascular endothelial growth factor (VEGF) therapy in the 
neoadjuvant sett ing suggest improved pathologic complete response rates, especially in TNBC, studies to 
date have not demonstrated a survival benefi t in the adjuvant sett ing or metastatic sett ing.
A promising fi eld of clinical research in breast cancer is the use of immune checkpoint inhibitors. By 
blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these treatments are 
designed to enhance pre-existing anti-cancer immune responses. Several studies investigating checkpoint 
inhibitors are currently enrolling breast cancer patients. Approximately 20% of TNBCs express PD-L1, and 
expression of PD-L1 is associated with poor prognosis, thus making this aggressive phenotype att ractive 
subtype in which to investigate PD-L1 blockade.
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S4 – Genomics and epigenomics in cancer research and their potential use 
in diagnostics, prognostics and therapy
 Zlatko Dembić
Molecular Genetics Laboratory, Department of Oral Biology, Faculty of Dentistry, University of Oslo, Norway
Genomic, epigenomic and proteomic (-omic) analyses of 50 diﬀ erent types of most frequently occur-
ring malignant tumors (and over 10 rare ones) are in the focus of current research involving top Institu-
tions and Universities around the globe led by the National Cancer Institute (NCI) at the National Insti-
tutes of Health (NIH) and Human Genome Sciences in the USA.
Why is it important to look for changes not only in the genome but also in the epigenome of cancer, 
and primarily in cancer stem cells? Studying cancer has revealed defects in genes that drive the develop-
ment and growth of a large number of diﬀ erent tumors and their subsequent transformation into a malig-
nant state. The cancer stem cell, through numerous mutations progressively evolves into a more aggres-
sive phenotype, which ultimately ends with metastatic spreading. Epigenetic changes seem to contribute 
to a signifi cant level in these events, and studies should reveal their frequency, patt ern and role in various 
types of cancer. All this information will further improve our understanding of the biology of cancer and, 
in turn, would lead to new methods of diagnosing, classifying, predicting the outcome and treating the 
disease. For example, novel cancer-specifi c mutations and/or epigenetic changes are reasonable targets for 
therapeutic intervention. However, not all of them could turn out to be useful, as a large part of mutations 
of most solid cancers are random and have almost no infl uence to the course of the disease. They are pre-
dominantly a consequence of a failure in the genetic repair machinery. This usually occurs at a stage when 
cancer stem cell becomes genetically unstable and accelerates its mutation rate. Pathophysiologic factors 
that are involved in the development of cancer would only be found if we exclude the contribution of 
“false-positive” ones due to haphazardness of mutations at terminal stages of the disease. There are 
numerous methods aimed at studying cancer -omics in the search for novel therapeutic targets, and some 
of them will be presented and explained during the presentation.
Recent introduction of cancer immunotherapies signals hope to development of more successful 
standards in medical oncology. Majority of clinical research and trials is currently oriented towards fi nd-
ing new immune-checkpoint inhibitors or a combination of already existing ones (anti-PD1, anti-CTLA4) 
with chemotherapies. In addition, new -omics’ research information will defi nitely have the highest poten-
tial to develop bett er prevention and treatment strategies.
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S5 - Aggressive variant of castration resistant prostate cancer: Case report
 Milena Gnjidić
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia
A subset of patients with castration-resistant prostate cancer (CRPC) may present with distinct clini-
cal features, diﬀ erent from the classic prostate adenocarcinoma, including rapidly progressive disease 
with bulky symptomatic tumor masses, exclusive visceral metastases, a predominance of lytic bone metas-
tases, relative low prostatic-specifi c antigen ( PSA) concentration and resistance to androgene ablation. 
Biopsies performed in such patients may show poorly diﬀ erentiated carcinomas, neuroendocrine, small-
cell or mixed carcinomas. This aggressive tumors often demonstrate low or absent androgen receptor (AR) 
expression and sometimes express markers of neuroendocrine diﬀ erentiation. Patients meeting clinical 
criteria of aggressive prostate cancer have been shown to have poor prognosis and should be considered 
for platinum-based chemotherapy.
Toward development of a precision medicine, many next-generation sequencing studies have led to 
signifi cant advances in understanding of genomic alterations in prostate cancer. Except the most common 
genomic aberrations like fusion of TMPRSS2-ETS and mutations in TP53, AR, RB1 and PTEN/PIK3CA, 
there is a lot of interest in somatic and germline aberrations in DNA repair genes, such as BRCA2 and ATM 
that can be targeted by platinum and PARP inhibitors.
This is the case of 62-year-old patient with initially metastatic prostate adenocarcinoma, who, after a 
period of one year of disease control with androgen ablation, was diagnosed with CRPC with relative low 
PSA, bulky cholin PET - positron emission tomography negative liver metastases. Treatment with docetaxel 
chemotherapy failed. Biopsy of liver metastases showed small-cell carcinoma with neuroendocrine dif-
ferentiation. Subsequently he was treated with combination chemotherapy with cabazitaxel/carboplatin 
without response. The combination chemotherapy with cisplatin/etoposide achieved excellent clinical and 
a good radiological and biochemical response. The response was short-lived and patient died.
The aim of this presentation is to stress the importance of recognition of the aggressive variant of 
prostate cancer to improve patients outcomes. It should serve as a reminder that not all prostate cancer 
share the same biology and that androgen receptor is not the sole driver of this disease.
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S6 - Primary mediastinal germ cell tumors: Case reports
 Milena Gnjidić
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia
Germ cell tumors are called extragonadal if there is no evidence of a primary tumor in the testis. They 
are rare, 1-5% of all germ cell tumors, with the mediastinum and the retroperitoneum being the most com-
mon primary sites in adults. Pathogenesis and histology are identical to gonadal (testicular) germ cell 
tumors, both are devided into seminomas and non-seminomas, but with diﬀ erent biology and prognosis. 
According to one hypothesis they are derived from primordial germ cell that fail to complete the normal 
migration to the testis during embryonal development. Like their testicular counterparts primary medias-
tinal germ cell tumors occure typically in young men, but their prognosis is worse.
Treatment of extragonadal tumors is similar to treatment of testicular germ cell tumors. Standard 
treatment approach of mediastinal germ cell tumors consists of four courses of cisplatin-based chemo-
therapy followed by surgical resection of the residual tumor in non-seminomas. Primary mediastinal non-
seminomas carry a poor prognosis with 40-50% overall survival after cisplatin-based chemotherapy and 
surgery. In contrast, mediastinal seminomas have a good prognosis with 88-90% overall survival.
I presented two young men with primary mediastinal non-seminomas but with diﬀ erent tumor biol-
ogy and clinical outcome. One tumor was inoperable and treated with cisplatin-based chemotherapy, 
tandem high-dose chemotherapy supported by hematopoietic stem-cell transplantation and salvage che-
motherapy, but the patient died of disease progression. The other was operable and was treated with cis-
platin-based chemotherapy followed by surgery with complete resection.
Primary mediastinal non-seminomas have very poor prognosis. The most important is that the stan-
dard treatment is cisplatin-based chemotherapy followed by surgery.
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S7 - Biological therapy of malignant melanoma
 Davorin Herceg
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia
BRAF mutations are present in 40-60% of melanomas. BRAF inhibitors vemurafenib, dabrafenib and 
encorafenib are used only when a BRAF mutations is present. In comparison with chemotherapy-dacarba-
zine, BRAF inhibitors used in monotherapy show similar improvements of the overall survival (OS), pro-
gression free survival (PFS) and response rate (RR). Resistence to BRAF inhibitors monotherapy develops 
after 5-7 months of median PFS. The resistance to BRAF inhibitors is associated with a rapid recovery of 
the MAPK pathway correspoonding to a rapid clinical progression. A complete inhibition of the MAPK 
pathway is obtained by the combination of BRAF and MEK inhibitors which may delay or prevent MAPK-
dependent resistance. Another advantage of this combination is that the paradoxical activation resulting 
in BRAF wild-type melanomas may be reduced, what diminishes adverse events (AEs).
Combination of BRAF and MEK inhibitors are analyzed in three randomized phase 3 clinical trials. In 
all clinical studies the valuable and consistent results are shown. After three years, in the arm of BRAF+MEK 
combination therapy 44% of patients are alive, in comparison with anti-BRAF monotherapy (32% are 
alive). Similar results are obtained with vemurafenib + cobimetinib combination (37% patients survived 
three years).
In combination studies of BRAF and MEK inhibitors, LDH value, ECOG performance status and the 
number of metastatic sites have impact on OS and RR.
The more frequently resported AEs with the combination therapy are: pyrexia in 53% of patients, 
paraesthesia in 31% of patients. AES which are less evident with anti-BRAF monotherapy than in combi-
nation, such as decrease of cardiac EF and chorioretinopathy, which are more frequent in combination; 8% 
and 1% respectively, but all skin manifestations, including squamous carcinoma are less common.
The quality of life is improved in combination therapy with BRAF and MEK inhibitors in comparison 
with anti-BRAF monotherapy.
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S8 - What is optimal treatment for majority of NSCLC patients: 
Treatment of patients with NSCLC without activating mutations
 Marko Jakopović,  Miroslav Samaržija
Department for Respiratory Diseases ‘Jordanovac’, University Hospital Center Zagreb, University of Zagreb, 
Medical School, Croatia
Lung cancer is the most common cause of death among malignant diseases in the World and it is 
responsible for almost 1.5 million deaths worldwide each year. According to histology, lung cancer is 
divided in two majors soubgroups: small cell lung cancer, which accounts for around 15% of all cases, and 
non-small cell lung cancer (NSCLC). Non-small cell lung cancer is further dovided accodring to histology 
subtypes to adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Around 20% of patients 
with non-squamous NSCLC harbour activating mutations in EGFR or ALK gene and therefore can be 
treated with targeted therapies like EGFR tyrosine-kinase inhibitors (gefi tinib, erlotinib, afatinib) or ALK 
inhibitors (crizotinib, ceritinib, alectinib). Still, vast majority of patients with advanced NSCLC are candi-
tates for systemic treatments. In patients with advanced squamous cell lung cancer, initial systemic treat-
ment is platinum – based doublet (either cisplatin or carboplatin) with cytotoxic agents of third generation 
like gemcitabine, vinorelbine, paclitaxel or nab-paclitaxel. In patients with non-sqaumous histology, initial 
cytotoxic treatment is also platinum based doublet, but prefered combination is pemetrexed with cisplatin 
or carboplatin. Above mentioned platinum –based doublets are also option in upfront tretametnt of non-
squamous NSCLC. In patients who are initially treated with pemetrexed and cisplatin, after four to six 
cycles re-evaluation is required and in patients with stable disease, partial or complete response mono-
therapy with pemetrexed is indicated until progression of the disease. Maintanance treatment with peme-
trexed signifi cantly prolongs survival compared to standard 4-6 cycles of platinum-based doublet chemo-
therapy. Other initial option in patients with non-squamous NSCLC is additon of anti-VEGF drug bevaci-
zumab to paclitaxel-carboplatin combination. Mentioned triplet extended survival for more than two 
months compared to paclitaxel-carboplatin alone. Choice between two options is left to the physicians and 
availabilty of the drugs in each country. In recent years, immunotherapy has emerged as new treatment 
option in patients with lung cancer. Recenet phase III trial in highly positive PD-L1 patients showed supe-
riority of pembrolizumab over platinum-based chemotherapy doublet prolonging both progression-free 
and overall survivall. Unfortunately, nivolumab didn’t show the same eﬃ  cacy in phase III trial as pembro-
lizumab.
In conclusion, vast majority of paients with non-small cell lung cancer don’t harbour activating 
mutaions and are candidates for chemotherapy treatments. Small fraction of patients, approximately 1/3 
of them, who express high positivity of PD-L1, can be candidates for pembrolizumab treatment.
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S9 - Access to innovative medicines for metastatic melanoma in South-East Europe
 Lidija Kandolf Sekulovic
Interdisciplinary Melanoma Team, Department of Dermatology, Military Medical Academy, Belgrade, Serbia
A tremendous breakthrough in oncology has been made with the recent developments, with targeted 
therapy and immunotherapy for diﬀ erent cancers, including metastatic melanoma. These developments 
are accompanied by signifi cant rise in unit price of medicines and also their number, leading to the rise in 
share of expenditure for oncology drugs, and in many countries, including countries of South-East Europe, 
to the restricted access to these medicines. 
In a recent survey of the European Association of dermatologic oncology, a great discrepancy exists 
in metastatic melanoma treatment across Europe, with restricted access in countries to fi rst-line recom-
mended treatments per current guidelines: combination BRAFi and MEKi, and anti-PD1 immunotherapy. 
These restrictions were in correlation with health expenditure per capita and human development index, 
as well as with a health policy performance scores for each country, and will prove to signifi cantly aﬀ ect 
the overall survival of this group of patients. While in Greece, Slovenia and Bulgaria innovative medicines 
are reimbursed after a relatively short delay, in majority of other countries of SE Europe there is a signifi -
cant delay in reimbursement. In Croatia, fi rst-line targeted therapy and anti-PD1 immunotherapy are fully 
reimbursed from 2017. In Serbia BRAFi monotherapy (not the combination) and immunotherapy only for 
BRAF negative patients are reimbursed from 2017. In Romania, Albania and Montenegro, only BRAFi 
monotherapy is reimbursed, while in Bosnia and Herzegovina innovative medicines for metastatic mela-
noma are still not reimbursed. Similar results were obtained for other cancer types in a recent ESMO study 
that showed a large diﬀ erence in the availability of innovative agents for cancer treatment, particularly for 
metastatic melanoma, renal cell cancer and non-small cell lung cancer where access to innovative drugs 
defi nes therapeutic outcome, classical oncological treatment being mostly ineﬀ ective. Several eﬀ orts of the 
European Commission, oncological organizations and patient organizations are underway to improve the 
access to innovative medicines. Also, pharmaceutical industry is developing several aﬀ ordability strate-
gies and risk/sharing agreements with the national insurance funds. However, further development of 
new access models will be mandatory, as well as harmonization of health technology assessment strate-
gies and reimbursement process throughout Europe. Also, a constant adaptation to the latest development 
in medicine in national healthcare systems is crucial to substantially improve the current situation of can-
cer care disparities. 
The access to innovative treatment for metastatic melanoma (but also for other cancer types) is a 
major public health problem in the majority of countries of South-East Europe. Therefore, it is crucial to 
continuously increase the awareness of national and European policymakers, oncological societies, mela-
noma patients’ associations and pharma industry regarding this issue.
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S10 - Immunotherapy of metastatic melanoma
 Janja Ocvirk
Institute of Oncology Ljubljana, Slovenia
The incidence of melanoma in both males and females continues to rise during the past 40 years 
despite the stable or declining trends for most cancer types. This aggressive disease accounts for approxi-
mately 75% of skin cancer related deaths. Historically, treatment options for patients with advanced stage 
melanoma have been limited by modest response rates and failure to improve overall survival. The treat-
ment landscape for advanced stage melanoma has changed since 2011 with the approval of ipilimumab 
(anti CTLA-4) antibody) and BRAF inhibitor vemurafenib, both of which improved overall survival in 
phase III clinical trials. Since then programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab and 
nivolumab, second BRAF inhibitor dabrafenib and MEK inhibitors trametinib and cobimetinib, have 
greatly extended the potential for the treatment success for advanced melanoma. Overall survival rate and 
long-term benefi ts had been signifi cantly increased with pembrolizumab and nivolumab in multiple large 
clinical trials. Combination of nivolumab and ipilimumab is even more eﬀ ective than nivolumab or ipili-
mumab alone, however it is more toxic, too. The adverse events associated with these new treatments are 
generally tolerable and mild to moderate in severity; however, care should be taken when selecting a 
therapy, since the specifi c adverse events associated with these treatments are unique, and serious events 
have been reported.
Therapeutic decisions are complicated by the need to consider patient and disease characteristics, 
individual treatment goals as well as the diﬀ erent eﬃ  cacy and safety profi les of agents with varying mech-
anisms of action and depending on the line of treatment. Long-term survival of patients with advanced 
melanoma is now a realistic goal, creating the additional need to re-establish how clinical benefi t is evalu-
ated. Future will bring also diﬀ erent combinations and sequencing approaches of current treatments 
which is expected to increase the number of patients who experience clinical benefi t.
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S11 - Hepatocellular carcinoma
 Janja Ocvirk
Institute of Oncology Ljubljana, Slovenia
Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to their optimal 
care. The Barcelona Clinic Liver Cancer algorithm is the most widely used staging system. Patients with 
single liver tumors or as many as 3 nodules <3 cm are classifi ed as having very early or early-stage cancer 
and benefi t from resection, transplantation, or ablation. Those with a greater tumor burden, confi ned to 
the liver, and who are free of symptoms are considered to have intermediate stage cancer and can benefi t 
from chemoembolization if they still have preserved liver function. Those with symptoms of HCC and/or 
vascular invasion and/or extrahepatic cancer are considered to have advanced-stage cancer and could 
benefi t from treatment with the kinase inhibitor sorafenib. Patients with end-stage HCC have advanced 
liver disease that is not suitable for transplantation and/or have intense symptoms. Studies now aim to 
identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages 
and bett er predict their survival time and response to treatment.
Sorafenib is now the standard systemic therapy for HCC. In a phase 3 SHARP trial performed in the 
West, sorafenib reduced patients’ risk of death by 30% (median survival time of 10.7 months with sorafenib 
vs 7.9 months without). In a trial performed in the East, patients had shorter survival times because they 
entered the study with more advanced-stage HCC; median survival times were 6.5 months with sorafenib 
versus 4.2 months without. The magnitude of improvement was the same in each study, indicating that 
the drug is active in diﬀ erent populations. The most frequent adverse events are hand/food/skin reactions, 
asthenia, diarrhea, and arterial hypertension, the incidence of which is higher in Asian patients. Up to 30% 
of the patients have to discontinue treatment because of adverse events, but adverse events (all dermato-
logical AE in fi rst 60 days) correlate with a bett er outcome. Careful management of patients and appropri-
ate dose adjustments are therefore needed.
Sorafenib is the fi rst treatment option for patients with HCC of BCLC stage C and for patients with 
HCC of BCLC stages A or B who are not candidates for curative or locoregional treatments due to treat-
ment stage migration and/or untreatable progression because of tumor burden. Sorafenib improves over-
all survival of patients with HCC with the absence of objective responce. Thus, time to tumor progression 
(TTP) is used to capture benefi ts of novel molecular agents, but proof of its surrogacy with survival is 
lacking. This was the reason that treatment was continued beyond progression in the sorafenib trials with 
refi nement of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Thus, PPS (postprogres-
sion survival) is infl uenced by progression patt ern and not solely by stimultaneous impairment of liver 
function and performance status.
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S12 - Role of angiogenesis inhibitors in treatment of ovarian carcinoma
 Anes Pašić,  Timur Cerić,  Semir Bešlija
Oncology Clinic, Clinical University Center of Sarajevo, Bosnia and Herzegowina
Ovarian cancer is the most lethal gynecologic cancer.A signifi cant unmet clinical need exists in ovar-
ian cancer, with no treatment innovation over the past 15 years and minimal improvement in outcomes. 
Angiogenesis seems to play a major role in the natural history of ovarian cancer, promoting tumor growth 
and progression in the form of ascites formation and metastatic spread creating a strong rationale to use 
angiogenesis inhibitors to improve patient outcomes. Bevacizumab , recombinant humanized monoclonal 
IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A is the angiogenesis inhibitor that 
has been most extensively studied in ovarian cancer.
Two phase II trials indicate that bevacizumab has single-agent activity in ovarian cancer., both in 
terms of response rates and progression free survival.
Four phase III randomized trials have been published evaluating the addition of bevacizumab to 
standard chemotherapy as front-line treatment of advanced ovarian cancer(GOG-0218, ICON 7) and eval-
uating the combination with chemotherapy in recurrent ovarian cancer (OCEAN trial for platinum-sensi-
tive and AURELIA trial for platinum-resistant disease).
All these trials showed a statistically signifi cant improvement in progression-free survival with no 
improvement in overall survival has been reported. Although, in ICON 7 trial, an exploratory analysis of 
502 patients who had disease with poor prognosis showed a signifi cant diﬀ erence in overall survival of 
over 4 months in women who received bevacizumab plus chemotherapy compared to those who received 
chemotherapy alone.
Many questions remain to be answered regarding the optimal use of bevacizumab in patients with 
ovarian cancer. These include the optimal dose and duration of treatment. It remains unclear whether 
bevacizumab maintenance needs to be extended untill disease progression, as it was done in trials for 
recurrent ovarian cancer. These studies showed a larger hazard ratio for PFS favoring the use of bevaci-
zumab suggesting that administration until progression may represent the optimal schedule. Another 
question is can biomarkers identify the groups more likely to benefi t from bevacizumab? Eﬀ orts to iden-
tify biomarkers with potential prognostic and predictive value in ovarian cancer patients treated with 
bevacizumab are critical in selecting patients for therapy and are the subject of ongoing research.
There are several ongoing trials evaluating the optimal timing of bevacizumab, duration of treatment, 
benefi t in continuing beyond progression and re-challenging bevacizumab in ovarian cancers.
In conclusion, we can say that amongst new biologic drugs, bevacizumab is the fi rst agent to show 
clear therapeutic activity in recurrent disease and fi rst-line therapy along with an acceptable toxicity 
 profi le.
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S13 - Metastatic non-small cell lung cancer treatment algorithm in Croatia
 Sanja Pleština
Department of Respiratory Diseases ‘Jordanovac’, University Hospital Center Zagreb, 
Medical School University of Rijeka, Croatia
Lung cancer is the most common malignant disease in men and third is the occurrence of women in 
the Republic of Croatia, and rates of incidence and mortality are continuously increasing. According to the 
Pulmonary Departement of University Hospital Centre Zagreb data, 60% of the patients suﬀ er from lung 
adenocarcinoma while about 30% have squamous cell carcinoma and 10% non-small cell lung cancer 
(NOS).
The standard fi rst-line treatment for advanced non-small cell lung cancer patients is platinum-based 
chemotherapy dublet with the addition of a third-generation cytotoxic agent (gemcitabine, vinorelbine, 
taxanes), which has been approved for Croatian patients as well. According to ESMO Guidelines, the use 
of nab-paclitaxel is indicated in selected patients, which has not been approved for the treatment of lung 
cancer patients in our country, as well as the addition of necitumumab to gemcitabine and cisplatin in the 
fi rst-line treatment for patients with squamous cell carcinoma expressing EGFR by IHC. In the fi rst line 
treatment according to CHIF guidelines, patients with non-squamous lung cancer can not be treated with 
pemetrexed nor with bevacizumab, although this therapy is a standard of treatment for many years in 
Europe and all over the world.
The standard second line treatment is monotherapy with pemetrexed or docetaxel both in Europe 
and in Croatia. The addition of ramucirumab (all) or nintedanib (NSCC) to docetaxel is not a standard of 
treatment nor the use of erlotinib in patients with wild type EGFR or afatinib for the treatment of SCC in 
Croatia. Immunotherapy with nivolumab or pembrolizumab is not an treatment option according to CHIF 
guidelines.
EGFR mutated patients may receive EGFR tyrosine kinase inhibitors in the second line treatment 
after chemotherapy only, without the use of bevacizumab, and in the case of disease progression and 
positive mutation T790M, the use of osimertinib has not yet been approved. ALK + patients may receive 
crizotinib in the fi rst line, which is the standard of treatment according to all valid guidelines, while in later 
treatment lines after the progression of the disease it is not possible to get second generation ALK TKI at 
the expense of CHIF and the therapeutic option is chemotherapy treatment.
Although the need to amend the insurers guidelines for the treatment of patients with non-small cell 
lung carcinoma has been recognized in Croatia, the CHIF’s modifi cation process is considerably slower 
than the progress of medical knowledge, resulting in the inability to apply optimal patient treatment and 
contributing to a worse outcome and higher mortality.
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S14 - Breast cancer immunotherapy
 Lazar Popovic
Oncology Institute of Vojvodina, University Novi Sad, Serbia
In the era of the large number of innovative drugs metastatic breast cancer has become a chronic dis-
ease, due to the prolonged survival of patients over many years. However, the innovative drugs are mainly 
placed in the HER2 positive subtype, as well as with hormone therapy contribute to bett er treatment of the 
disease. Due to absence of target therapies, patients with triple negative breast cancer (TNBC) have a much 
poorer survival than other subtypes. On the other hand lage number of somatic mutations in TNBC, and 
frequently the presence of tumor-infi ltrating lymphocytes is an ideal ground for application of immuno-
therapy. Checkpoint inhibitors (anti-PD 1 / PD-L1 antibody), showed remarkable results in the treatment 
of TNBC. In the phase I atezolizumab, anti-PD-L1 antibody, had a response rate (ORR) of 33% in PD-L1 + 
TNBC. Also pembrolizumab, anti-PD-1 antibody is produced a remarkable results in same subset of 
patients. Shortly afterwards in phase Ib a combination of nab-paclitaxel and atezolizumab demonstrated 
the disease control (CR + PR + SD) in 89% of patients, which led to the design of the phase III trials. In addi-
tion, checkpoint inhibitors are tested in neoadjuvant and adjuvant phase of TNBC treatment. In non-TNBC 
subtypes checkpoint inhibitors have a lower response rate, and those subtypes required diﬀ erent strate-
gies of immunotherapy. The monovalent vaccines against HER2 antigen, although not prolonged time to 
progression (PFS) compared to placebo, gave some hope and intrigued researchers for further reasearc, 
since in patients in whom achieved response survival was extremely long. PANVAC, polyvalent vaccine, 
showed prolonged PFS combination with docetaxel in patients HER2 negative breast cancer. Immuno-
therapy has its place in the management of breast cancer, and we are looking forward to the fi nal results 
of phase III study checkpoint inhibitors.
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S15 - From personalized to precise medicine – current status of molecularly 
targeted therapy in advanced non-small cell lung cancer (NSCLC)
 Davorin Radosavljević,  Jelena Spasić
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Personalized medicine was a phrase used to explain a therapeutic approach in oncology that was 
aimed at optimising therapy for each individual patient. It is a humanized approach, but applicable only 
in a minority of patients, helped with the principles of pharmacogenomics. US National Institutes of 
Health proposed a more appropriate phrase, precision medicine, defi ned as an emerging approach for disease 
treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each 
person.
In the last two decades a great number of molecular targets, as a tumor’s growth driver were identi-
fi ed in the tumor cell of NSCLC. Unfortunately, a small number of eﬃ  cient drugs against those targets 
were successfully developed, most of them being small molecules, tyrosine-kinase inhibitors (TKI).
Epidermal growth factor and its receptor (EGFR) was the fi rst, in 2004. to demonstate therapeutic 
importance of the mutation of this receptor in lung cancer, and clinical benefi t from inhibition of one or 
more receptors in this receptor family. TKIs erlotinib and gefi tinib were developed fi rst, than it was noticed 
that Asian patients, women, non-smokers and those with adenocarcinoma have bett er respons to therapy 
and longer progression-free-survival (PFS), and lastly it was revealed that gene mutations of the EGFR 
gene are predictors of response to EGFR TKI. Those mutations are of diﬀ erent mechanisms, develop early 
in the tumor growth, located on exons 18-21 on chromosome 7. The frequency of these mutations is 10-15% 
in Caucasian patients, compared with more than 40% in Asian patients. After a median of 8-12 months of 
therapy with fi rst or second generation TKIs, most patients progress. In about half of them, the existance 
of a secondary mutation, T790M, has been discovered, and we are able to oﬀ er these patients osimertinib, 
a third generation TKI that may prolong PFS for another 10-12 months.
Anaplastic lymphoma kinase (ALK), a member of the insulin receptor tyrosine-kinase family, is 
encoded by the ALK gene on chromosome 2p23. In NSCLC it appears as a fusion gene, with ELK4 gene, as 
a result of a translocation between chromosomes 2 and 5. Its frequency in NSCLC is 3-7%, more common 
among patients with a never/light smoking history, adenocarcinoma histology, younger age, female gen-
der and in tumours wild type for EGFR and KRAS. Crizotinib as a TKI is an eﬃ  cient drug not only against 
ALK translocated tumors, but also against ROS1 mutated tumors, with a median PFS of up to 12 months. 
Today, we have a palett e of drugs with proven activity in second-line treatment (ceritinib, alectinib, briga-
tinib etc).
Precise medicine is today a reality in NSCLC treatment but only for about 20% of patients. The impor-
tance of even this small success lies in the enormous number of NSCLC patients worldwide. New thera-
peutic challenges are targeted therapy for squamous NSCLC patients, and the initial success of immuno-
therapy, that has diﬀ erent biomarkers and safety profi le. The start of precise medicine in NSCLC was 
successful, and this type of treatment will continue to rise in oncology of solid tumors.
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S16 - Survival strategies of cancer cells
 H. Joachim Seitz 
Institute of Biochemistry and Molecular Biology, University Hospital Hamburg-Eppendorf, Germany
With respect to tumor cell metabolism many of us still have the classical picture in mind: Tumor cells 
are energetically surviving by aerobic glycolysis, called Warburg Eﬀ ect, i.e. uptake of glucose and metabo-
lizing via glycolysis to lactate, winning just 2 ATP. Recently cellular and molecular oncologists investi-
gated the intermediary metabolism of glucose (and other molecules) in diﬀ erent tumor cell lines and dis-
covered:
–  Tu-cells are able slipping artfully through the vascular endothelium, then migrating into the tissue 
behind.
–  Tu-cells stimulate surrounding tissue to proteolysis in order to deliver essential amino acids for 
their own protein synthesis.
–  Tu-cells steel mitochondria from surrounding tissue, integrating them in their own tissue in order 
signifi cantly to increase cellular ATP supply.
–  Tu-cells, when located in oxygen deprived tissue, suppress the gene expression of their tumor 
 suppressor genes, gaining malignancy.
–  Tu-cells trigger in vivo the surrounding tissue to produce infl ammatory signals, with the conse-
quence that the hepatic circadian rhythm of the host is broken, and liver metabolism is switched to 
permanent glucose production for uninterrupted glucose supply of the Tu-cells.
These and other fi ndings hopefully will enable oncologists to develop new strategies of tumor ther-
apy by disrupting tumor cell metabolism in a tumor specifi c way. Certainly the application of 3-Brom-
pyruvate, used in single cases in Germany with fatal consequences, should be avoided.
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S17 - PARP inhibitors in ovarian cancer treatment
 Tajana Silovski
‘Radiochirurgia Zagreb’, Croatia
PARP inhibitors represent targeted therapy in ovarian cancer treatment. They are specifi cally active 
in cells that have impaired repair of DNA by the homologous recombination (HR) pathway. Cells with 
mutated BRCA have HR defi ciency which is also present in a signifi cant proportion of non-BRCA-mutated 
ovarian cancer.
BRCA mutations can be inherited (germ-line mutations) or acquired (somatic mutations).
Olaparib is the fi rst oral PARP inhibitor investigated in addition to chemotherapy and as mainte-
nance therapy following chemotherapy.
In maintenance, olaparib showed statistically improved progression free survival (PFS) (19,1 vrs 5,5 
months, p>0,0001) in patients with platinum-sensitive, relapsed BRCA-mutant ovarian cancer.
Clinical trials were also conducted with other PARP inhibitors (rucaparib, niraparib, veliparib) and 
those trials included also non-BRCA-mutated ovarian cancer.
Rucaparib is approved for the treatment of BRCA-mutated advanced ovarian cancer in patents who 
have received at least two prior lines of chemotherapy.
Niraparib has been recently approved for the maintenance treatment of patients with reccurent epi-
thelial ovarian, fallopian tube or primary peritoneal cancer regardless of BRCA mutation status.
High-grade ovarian cancers are more often platinum sensitive and moreover have the most underly-
ing defects in DNA repair. Furthermore, patients with high-grade, platinum sensitive ovarian cancers may 
also benefi t from PARP inhibitors irrespective of BRCA status.
Second-generation studies are investigating the combination of PARP inhibitors with anti-angiogenic, 
immuno-oncology and DNA-repair inhibiting agents.
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S18 - Liposomal irinotecan in the treatment of pancreatic cancer
 Marko Skelin
Hospital Pharmacy, General Hospital Šibenik, Croatia
Currently there is no consensus about the most benefi cial treatment as fi rst line for metastatic adeno-
carcinoma of pancreas, but there are two options that are preferred protocols according to NCCN guide-
lines (FOLFIRINOX vs nab-paclitaxel + gemcitabine- MPACT). Recently old drug but in new formulation 
had proven it eﬃ  cacy in a in a three-arm, randomized, open-label study (known as the NAPOLI-1 trial), 
which was conducted in 417 patients with metastatic pancreatic adenocarcinoma whose cancer had pro-
gressed after treatment with gemcitabine alone or in combination with other agents. Based on that trial, 
liposomal irinotecan was granted approval by regulatory agencies (FDA and EMA) for indication of a 
second line treatment after progression or failure due toxicity from gemcitabine base therapy. Liposomal 
irinotecan should be use in combination with fl uorouracil and leucovorin as this combination has proven 
to be superior compared to liposomal irinotecan monotherapy considering overall survival. Patients 
treated with this combination of liposomal irinotecan plus fl uorouracil+leucovorin lived for an average of 
6.1 months, compared with 4.2 months for those treated with only fl uorouracil+leucovorin in the control 
group, and 4.2 months for patients in another group who were treated with liposomal irinotecan alone. 
Liposomal preparations of drugs can have diﬀ erent toxicity profi le compared to their regular formulations 
together with diﬀ erent pharmacokinetic profi le. The aim of this lecture would be to present eﬃ  cacy and 
safety profi le of protocol consisting new formulation of irinotecan used in the treatment of pancreatic 
 cancer.
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S19 - Treatment algorithm of non-small cell lung cancer (NSCLC) 
in 2017 in Serbia
 Jelena Spasic,  Davorin Radosavljevic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Lung cancer is still one of the leading causes of death from malignant disease throughout the world. 
Each year, about 5200 new cases of lung cancer are diagnosed in Serbia. About 80-85% of these are NSCLC, 
while small-cell lung cancer (SCLC) represents about 15-20%. According to data from Serbian Institute for 
Public Health, lung cancer is the third most common cancer in women, and the second leading cause of 
death from malignant disease, while in men it is the most common cancer, and the leading cause of death.
When symptoms fi rst appear, a patient is seen by their primary care physician, who conducts initial 
diagnostics (usually chest x-ray). In case of fi ndings indicative of lung cancer, the patient is referred to a 
general hospital or a specialised tertiary cancer center or pulmonology clinic. Further diagnostic proce-
dures, CT scan and histopathologic diagnosis, most frequently by bronchoscopy, are conducted there. 
After a diagnosis of lung cancer is confi rmed, the patient is referred to a specialised cancer center, where 
a decision on the treatment course is made by a multidisciplinary team.
In Serbia, the availability of drugs used in the treatment of cancer is directed by the Drug List of the 
National Health Insurance Fund, and all state institutions must abide by it. The treatment of lung cancer 
patients is conducted in tertiary cancer and pulmonology centers, as well as oncologic and pulmonologic 
centers in general hospitals, according to teritorial accesibility.
Regardless of hystologic type of lung cancer, most third generation drugs are reembursed for fi rst 
and second line therapy: gemcitabine, paclitaxel, vinorelbin, as well as second generation drugs etoposide, 
cisplatin and carboplatin. Pemetrexed and bevacizumab are not reembursed for the treatment of lung can-
cer in Serbia. Docetaxel is reembursed in second-line treatment only for stage IIIb. Maintenance therapy as 
such is not recognised, but individual patients may be treated with gemcitabine maintenance.
Testing for EGFR activating mutations has been done in Serbia since 2011. in patients with adenocar-
cinoma, stage IIIb and IV. Gefi tinib, erlotinib and afatinib are reembursed for fi rst line therapy of EGFR 
mutation positive adenocarcinoma patients. Erlotinib is also reembursed for second line therapy of 
advanced lung adenocarcinoma patients who experienced high-grade toxicity of fi rst line therapy.
ALK testing is not routinely done in Serbia, since no ALK inhibitors are reembursed. Crizotinib is 
registered for treatment of lung adenocarcinoma patients. Testing for other gene abnormalities is also not 
routinely done.
Immunotherapy is not available in Serbia at this time.
Tertiary cancer centers usually have palliative and supportive care teams or units that are responsible 
for early integration of palliative care in the treatment of lung cancer patients. When a patient is at home, 
home care teams from primary health care are responsible for administering palliative/supportive care.
Over the last few years, we have seen an important improvement in the availability and accessability 
of drugs for the treatment of lung cancer in Serbia, but there are still important restrictions which make 
treatment of these patients challenging.
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S20 - HER2-positive breast cancer: Challenges and progress in the treatment
 Ljiljana Stamatovic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Advances that have been made over the past two decades in the treatment of patients with HER2-
positive breast cancer, both in the metastatic and in the neo/adjuvant sett ing, have dramatically improved 
the prognosis of HER2-driven BC. Since the introduction of trastuzumab, the fi rst anti-HER2 directed 
therapy, several other HER2-targeted agents have been successfully designed and approved for the treat-
ment of HER2-positive BC.
Numerous trials have studied a role of trastuzumab, a recombinant humanized monoclonal antibody 
that inhibits ligand-independent HER2 signaling, in all sett ings. The addition of trastuzumab to chemo-
therapy in patients with previously untreated MBC led to a signifi cantly higher objective response rate, 
prolonged time to progression and improved overall survival compared with chemotherapy alone. Fur-
thermore, the addition of trastuzumab to chemotherapy signifi cantly improved long-term disease-free 
survival and overall survival among patients with early-stage BC, while combining trastuzumab with 
chemotherapy in the neoadjuvant sett ing enabled higher pCR rates and longer event-free survival.
The introduction of lapatinib, a dual tyrosine kinase inhibitor of HER2 and EGFR, oﬀ ered new choices 
for patients with advanced HER2-positive BC, although the drug has failed to show eﬃ  cacy in the adjuvant 
sett ing. Patients with ABC/MBC who have already progressed on regimens that included trastuzumab, an 
anthracycline, and a taxane had a bett er TTP when they received lapatinib in combination with capecitabine 
compared with those who received capecitabine alone. These were the fi rst results to show that continuing 
HER2-targeted therapy after progression on a HER2-targeted regimen improves outcomes.
Pertuzumab is a novel humanized monoclonal antibody directed at the dimerization domain of 
HER2. Specifi cally, it inhibits ligand-dependent signaling between HER2 and HER3, which is known to 
activate a potent cell-survival signal. Because of the diﬀ erent binding sites, trastuzumab and pertuzumab 
have diﬀ erent but similar and complementary mechanisms of action. The combination of pertuzumab 
with trastuzumab and a taxane signifi cantly prolonged both PFS and OS compared with trastuzumab and 
docetaxel alone in MBC patients (CLEOPATRA). The benefi t of dual HER2 blockade with pertuzumab and 
trastuzumab was also confi rmed in neoadjuvant sett ing (NeoSphere, THRYPHENA), while the use of per-
tuzumab in the adjuvant sett ing is still being evaluated (APHINITY).
Trastuzumab emtansine (T-DM1), another novel anti-HER2 therapy, is an antibody-drug conjugate 
in which trastuzumab is stably linked to a potent microtubule inhibitor, a derivative of maytansine. This 
fi rst-in-class drug was developed in an att empt to overcome trastuzumab resistance. T-DM1 was com-
pared with lapatinib and capecitabine in the second-line, advanced-disease sett ing in the EMILIA study. 
Patients with HER2-positive MBC whose disease progressed on trastuzumab and taxane-based therapy 
had a signifi cantly longer OS in the T-DM1 arm compared with the control group. In the TH3RESA trial, 
a heavily pretreated patient population with advanced HER2-positive BC had signifi cantly improved PFS 
compared with physician’s choice therapy, providing further evidence of the activity and tolerability of 
T-DM1 against the current standard therapy.
Altogether, owing to the introduction of eﬀ ective anti-HER therapies, including trastuzumab, pertu-
zumab, lapatinib, and T-DM1, the outcome of patients with HER2-positive MBC has signifi cantly 
improved.The median survival time using these modern combination therapies is now approximately 5 
years compared with approximately 1.5 years in the pretrastuzumab era.
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Although the currently available anti-HER2 therapies have changed the natural history of HER2-
positive BC, new therapeutic options are necessary because the disease is essentially incurable in the met-
astatic sett ing and a relevant proportion of patients with early-stage disease still relapse in spite of the use 
of currently available neo/adjuvant therapies. Neratinib, a pan-HER tyrosine kinase inhibitor, is one of the 
most promising new drugs for HER2-positive BC. Other drugs, such as ONT-380 (an oral, small-molecule, 
HER2-selective inhibitor) and MM-302 (an anti-HER2 atibody-drug conjugate carrying pegylated liposo-
mal doxorubicin) have shown initial promising activity and good tolerance among patients with HER2-
positiveBC. Interest in the inhibition of downstream signaling of the HER2 pathway with mTOR/PI3K/Akt 
and CDK4/6 inhibitors is currently under clinical evaluation. Some immunologic approaches (vaccines, 
alone or in combination with trastuzumab, inhibitors of immune checkpoints) are also being tested in 
HER2-positive BC.
Deeper understanding of the biology of HER2-positive BC (mechanisms of resistance to HER2 
directed therapies, cross-talk between HER2 and ER, biomarkers, diﬀ erent mechanisms of action of mono-
clonal antibodies and signal transduction inhibitors) is necessary to further improve outcome of patients 
with HER2-positive BC.
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S21 - What is new in the treatment of recurrent, persistent or metastatic 
cervical cancer
 Robert Šeparović,  Ana Tečić Vuger
Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
Cervical cancer accounts for 9% of all new cancer cases per year, with the biggest incidence rate in 
developing countries. In Croatia in 2014, 307 women were diagnosed with this disease, and 130 of them 
died. Patients are mostly diagnosed at the age of 50-54 years. The underlying cause of the disease is most 
often HPV infection and hypoxia. The basis of treatment for recurrent, persistent or metastatic cervical 
cancer is a systemic antineoplastic therapy. Polychemotherapy was the usuall framework of treatment 
until the angiogenesis and it’s importance in the process of development of cervical cancer was recog-
nized. By the addition of bevacizumab (study GOG 240), the overall survival and time to progression of the 
disease were signifi cantly improved, and this treatment is now standard in developed world. Today, there 
is much talk about immunotherapy and a whole series of clinical studies are performed in the treatment 
of cervical cancer. The results are relatively modest. One study that should be emphasized is the one using 
Hinrich’s adaptive immunotherapy model, with which an excellent objective response was achieved, 
although it included a small number of patients. The use of the checkpoint inhibitor ipilimumab showed 
a modest partial response in 6% of the patients. In the Keynote 028 study, use of pembrolizumab has led to 
a response rate of 17%. The concept of the use of the Monocytogenes Monolithic bacterium as HPV antigen 
vector (Axalimogen fi lolisbac - HPV) is also very interesting and the results of this study (NRG 0265) are very 
promising (38% of patients survived for one year). To conclude, anti-angiogenic therapy is the fi rst tar-
geted therapy that has shown benefi t in overall survival combined with polychemotherapy, compared to 
the current standard of polychemotherapy alone. Immunotherapy studies are ongoing and represent new 
approach in treatment of recurrent, persistent or metastatic cervical cancer.
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S22 - Nutrition of oncology patients – new guidelines of the European Society 
for Clinical Nutrition and Metabolism (ESPEN)
 Robert Šeparović
Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
Tumor cachexia is a multifactorial syndrome characterized by loss of muscle mass (with or without 
fat loss) that can not be fully recovered by the standard nutritional support, resulting in progressive weak-
ening of the body functions. In 2011, a panel of international experts has developed a framework for the 
defi nition and classifi cation of tumor cachexia. Tumor cachexia should be understood as a continuity that 
begins with diagnosis of malignant disease. Our task is to recognize the right stage of tumor cachexia so 
that the patient could be provided with adequate nutritional support. We should not fully rely on our 
clinical assessment and it is necessary to standardize the assessment using diﬀ erent screening tools. The 
most commonly used NRS 2002 (Nutritional Risk Screening) is a validated tool. However, this tool is not 
specifi c for cancer patients, so today the Good Nutrition Practice (GNP) tool is also being implemented. 
The necessity of compulsory nutritive screening from the time of diagnosis of cancer is recognized by 
ESPEN in its new guidelines issued in 2016. In accordance with their recommendations, it is necessary to 
evaluate the intake of nutrients and symptoms aﬀ ecting the nutrition status after screening. Nutritional 
support is mandatory in all patients with nutritional risk for which curative or palliative surgery is planned; 
in patients planned for radiation therapy, especially of head and neck, chest and gastrointestinal tract; and 
during systemic antineoplastic therapy. If oral ingestion of nutrients is insuﬃ  cient, if necessary, enteral 
and parenteral nutrition should be initiated. Access to nutritional status must be regular and multiprofes-
sional and should last for the entire duration of the disease. Treatment of cachectic patients must be mul-
timodal, and it includes nutrition, exercise and pharmacological preparations. It is recommended to take 
omega-3 fatt y acids (at least 2 grams per day) as it consequently reduces the formation of infl ammatory 
mediators, improves appetite and aﬀ ects body mass increase. It is necessary to increase the share of energy 
obtained by fat degradation rather than the share obtained by decomposition of carbohydrates.
A timely staging of tumor cachexia, the initiation of a multimodal approach within the multiprofes-
sional team and following the ESPEN guidelines is necessary to infl uence the quality of life of cancer 
patients and all other patients in nutritional risk.
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S23 - Options and sequencing of systemic treatment of metastatic renal 
cell carcinoma(mRCC) – clinical practise and clinical guidelines
 Breda Škrbinc
Institute of Oncology Ljubljana, Slovenia
The last 10 years bear witness to a dramatic change in the treatment portfolio of mRCC. This is pri-
marily due to our bett er understanding of RCC molekular biology and the consequent evolution of tar-
geted treatment. After a long period of very limmited eﬃ  ciency of cytokne treatment of mRCC, tyrosine 
kinase inhibitors, sorafenib and sunitinib, were the fi rst new treatment modalities registered in the years 
2005 / 2006. Based on the results of a phase III clinical trial which confi rmed a signifi cant PFS and OS benef-
fi t of sunitinib compared to interferon-α (IFα) in fi rst line mRCC treatment, sunitinib became the new 
standard fi rst line treatment option for mRCC patients. A signifi cant PFS as well an OS benefi t of the com-
bination of bevacizumab (monoclonal VEGFR antibody) with IFα compared to IFα monotherapy was 
confi rmed in two other clinical trials. However, due to the sc application of IFα and iv application of beva-
cizumab as oposed to the oral use of TKI, this drug combination remained sutable only for a limited group 
of patients with mRCC. based on the results of two studies, a pivotal study comparing the eﬃ  ciency and 
toxicity of another TKI, pazopanib, to placebo in the mRCC group of treatment naive patients and in the 
patients who had progressed on cytokine treatment and a noninferiority study which prooved the nonin-
feriority of pazopanib in comparison to sunitinib, pazopanib became another standard option for fi rst line 
treatment of mRCC patients. Based on numerous clinical studies, there are currently 9 targeted agents 
registred for the treatment of mRCC patients: sunitinib, sorafenib, pazopanib, axitinib, cabozantinib and 
lenvantinib from the TKI family, mTOR inhibitors: temsirolimus and everolimus, and fi nally, the VEGFR 
monoclonal antibody bevacizumab. In fi rst line treatment, the use of sunitinib or pazopanib is recom-
mended, based on the patient’s individual profi le, most importantly their comorbidities and the expected 
toxicity profi le. In some cases sorafenib and bevacizumab with IFα are used as a fi rst line option as well. 
Everolimus, axitinib, sorafenib, cabozantinib and the combination of lenvatinib and everolimus are tar-
geted therapies used in 2nd and further lines of mRCC treatment. In 2015 the renesance of immune treat-
ment emerged with the results of the CHECKMATE 025 study, which confi rmed a survival benefi t of 
patients treated with nivolumab (a PD-1 inhibitor) over the group of patients treated with everolimus in 
the 2nd line mRCC treatment following the progression on the anti-VEGFR therapy. Despite the improve-
ment of treatment due to targeted therapy, a cure for mRCC patients is still far out of sight. The challenges 
of the mRCC treatment in the near future remain the prognostic and predictive factors of mRCC, eﬃ  cient 
new drugs as well as new methods of sequencing and combination schemes.
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S24 - Anticoagulant therapy in patients with cancer
 Miomir Šoškić
Hospital Pharmacy, Clinical Center of Montenegro, Podgorica, Montenegro
Venous thromboembolism or VTE represents a major health problem that is not uncommon among 
patients with cancer and is one of the major causes of mortality and morbidity. Patients with malignant 
disease have a greater tendency to develop hypercoagulable state, and therefore a greater propensity to 
venous thromboembolism compared with patients without diagnosed cancer. VTE represents the second 
leading cause of death in patients with malignant disease, immediately after the mortality resulting from 
complications of cancer. Thromboembolism encompasses two interrelated conditions that are part of the 
same spectrum, pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). Association 
between idiopathic venous thromboembolism and occult malignancy has been observed in the 19th cen-
tury by Prof. Trousseau. However, emerging data indicated that venous thromboembolism is multifacto-
rial condition and absolute risk depends on the presence of several factors, such as age of the patient, 
prolonged immobilisation, surgery, type of tumor, stage of disease, use of hormone- and/or chemo- ther-
apy, the presence of a central venous catheter, duration of anesthesia, as well as the previously confi rmed 
diagnosis. The risk of DVT in patients with malignancy could be reduced by prophylactic methods, with 
their restriction in all risk clinical cases that have a tendency of recurrent thrombosis, serious bleeding and 
the emergence of other comorbidities. Therefore, the use of the prophylactic method is directed to the 
patient as non-pharmacological and pharmacological treatment. The goal of the non-pharmacological 
method is to achieve an augmentation of venous blood fl ow especially in lower limbs with passive exer-
cise, walking and use of external mechanical medical devices. From the point of pharmacological approach 
to treatment, we have a treatment for our patients that is directly oriented to the use of diﬀ erent antico-
agulant drugs, such as unfractionated heparin, low molecular weight heparins, inhibitors of activated 
factor X and/or the use of oral anticoagulants.
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S25 - Tumor infi ltrating lymphocytes (TIL) and androgene receptors (AR) 
in triple – negative breast cancer (TNBC) – new biomarkers on horizon?
 Ana Tečić Vuger,  Robert Šeparović
Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
Triple Negative Breast Cancer (TNBC) makes a clinically heterogeneous group of tumors, with the 
common feature of the most aggressive and deadliest breast cancer subtype. TNBC patients have higher 
rates of tumor disease return and worse overall survival than other breast cancer subtypes. The molecular 
feature of TNBC is the lack of immunohistochemical expression of estrogen receptors (ER), progesterone 
receptors (PR), as well as HER2 receptors. Approximately 12-17% of breast cancer patients have TNBC and 
they fall into the group of patients with poor prognosis, with  no eﬀ ective endocrine therapy or HER2-
mediated drugs. Due to the frequency of mutations (resulting in immune response inducing neo-antigens), 
the increase in the number of infi ltrating lymphocytes (TILs) (evidence of immune detection) and the 
increased expression of PD-L1 protein (inhibits T-cell anti-tumor response), TNBC represents a potential 
target for immunotherapy (especially PD-L1 targeted therapy). The TILs have prognostic value in TNBC, 
predictive of the eﬀ ect of preoperative chemotherapy, and may be associated with the eﬀ ectiveness of the 
use of immunotherapy with checkpoint inhibitors. There are currently controversies over the estimation 
of TILs role in breast cancer, both localization and quantifi cation. Namely, it appears that the stromal TILs 
have a higher prognostic value than the intratumor TILs, and the cut-oﬀ  value is also unclear (high versus 
low expression). The role of lymphocyte count in the blood is also unclear as a prognostic factor in TNBC. 
The predicted value of TILs in TNBC was investigated, depending on the type of chemotherapy applied 
and the greater expression of TILs was shown to be associated with a bett er outcome. More pronounced 
TILs are associated with a higher rate of complete pathological response to preoperative chemotherapy in 
TNBC. The basic expression of TILs may be associated with a bett er response to the use of a checkpoint 
inhibitor atezolizumab.
Androgen Receptors (AR) belong to a group of nuclear receptors, as well as ER and PR. AR is struc-
turally similar to progesterone receptor and progestins at higher concentrations block AR. AR are expressed 
in over 70% of breast cancer. Also, part of the TNBC has an expressed AR, although there is no expressed 
ER or PR. In literature, the presence of AR in TNBC ranges from 10-54%. Negative AR expression is sig-
nifi cantly associated with higher clinical stage, higher mitotic index, higher grade and high Ki-67 prolif-
eration index, and signifi cantly more AR negative tumors are seen in the group of tumors with positive 
basaloid immunophenotype and basaloid morphology. At present, there are good results of clinical stud-
ies with the application of immunotherapy, PD-1 and PD-L1 inhibitors, pembrolizumab and atezolizumab, 
in TNBC. Also, early clinical studies have shown promising results in the use of antiandrogens in the 
advanced TNBC.
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S26 - Reccurent ovarian cancer (ROC): treatment recommendations 
and every day clinical practice
 Zorica Tomašević
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Approximately 70% of ovarian cancer patients are diagnosed in FIGO III/IV stages when the chances 
for cure are limited even after optimal cytoreduction and platinum based fi rst line chemotherapy.
Relapses occurred in approximately 70-80 % of patients usually within fi rst 3 years (median 18 
months) after initial diagnosis. Relapsed ovarian cancer (ROC) is generally incurable disease; however 
time to progression and subsequent treatment as well as survival might be prolonged dependant on eﬀ ec-
tiveness of systemic treatment and less often also on relatively indolent biology of some cancers.
Gold standard of ROC treatment is re- challenge with platinum based chemotherapy, dependant of 
platinum free interval (PFI).
PFI represents sensitivity to platinum and is defi ned as the interval between last platinum dose and date 
of relapse. In every day clinical practice, this is the most widely accepted simple clinical surrogate for chemo-
therapy response/resistance prediction, also representing important criteria for prognosis predictions. PFI 
stratify patients in 4 cohorts: (1) platinum refractory - progression during platinum treatment or within <1 
month after last planed dose; (2) platinum resistant - progression within 1-6 months; (3) partially platinum 
sensitive - progression after 6-12 months; and (4) platinum sensitive - progression after >12 months.
Although this is widely used method for platinum sensitivity prediction, it has some limitation. 
Relapses can be diagnosed in a various ways dependant on follow-up practice that could directly infl uence 
PFI defi nition.
For instance, ROC might be diagnosed only upon CA125 increase while patient is completely free of 
detectable metastases and symptoms. Marker increase might proceed to symptomatic/imaging detectable 
relapse for months.
ROC might be diagnosed with more sophisticated imaging methods PETCT that might detect very 
small, asymptomatic lesions, or can be ultimately diagnosed clinically upon symptoms development, and 
then confi rmed by other tests.
All that issues have been discussed during several Ovarian Cancer Consensus Conferences (OCCC), 
and it was suggested that method used to diagnose ROC should be mandatory recorded especially if treat-
ment is planned in clinical trials. However, clinical trials with new drugs for ROC are rare, focused on fi rst 
or second line treatment and majority of patients are treated according to (local) guidelines. Some eﬀ ective 
drugs are unavailable in lower income countries.
Patients with platinum sensitive ROC are usually re-challenged with platinum based (carboplatin/
paclitaxel) chemotherapy, and dependant on response and duration of response, the same regimen might 
be repeated in further relapses. Major problem in repeating platinum is development of hypersensitive 
reactions (HSR). Risk increases with platinum lines and might develop in ~ 40% of patients treated with 
carboplatin in third line. Short PFI predicts lower responses and worse outcome also with non platinum 
drugs that includes single agents: paclitaxel (preferably weekly regimen), doxorubicin, gemcitabin (+ car-
boplatin if combined with bevacizumab). Maintenance with bevacizumab and PARP inhibitors (limited to 
patients with BRCA1/2 mutations) are eﬀ ective but are discussed elsewhere.
However, resistance to any treatment is just a matt er of time; and resistant relapses are a primary 
cause of death.
Lib Oncol. 2017;45(Suppl. 1), 1–42
30
S27 - Cooperation and experience of clinical pharmacist and oncologist 
through the case of a patient with colon cancer
 Olivera Spasovska1,  Biljana Grozdanovska2
1Hospital Pharmacy, University Clinic of Abdominal Surgery, Skopje, FYR Macedonia 
2University Clinic of Radiotherapy and Oncology, Skopje, FYR Macedonia
When we look at the multidisciplinary team working with cancer patients, we focus on the front line 
health care professionals - oncologist, pathologists, radiologists, nurses and other vital to providing the 
best care. But there is another major group of proﬀ esionals that has had to fi ght hard for recognition of 
their contribution. Pharmacist play a key role in the health care team through the provison of high quality 
medication, appropriate information on treatment schedules and eﬀ ects of medication, as well as advice 
on the management of adverse events and use of complementary treatment. Degree of implementation of 
clinical pharmacy practice in the health care system is diﬀ erent. The highest is in higly developed coun-
tries such as Canada, USA, UK.. in Europe, although there was some progress, it can not be said that phar-
maceutical services are fully implemented.
In Macedonia, there is a lack of clinical pharmacist, national guidelines and standard operative pro-
cedures for the responsibilities of clinical pharmacist. It is very important for clinical pharmacist to know, 
what are the expectations of health workers from them and why do they need pharmacist.
Through the case report about 72 – year old patient with adenocarcinoma of ascedent colon, after 
surgical procedure of right hemicolectomy and with liver metastases, with comorbidities such as arterial 
hypertension, diabetes mellitus, receiving chemotherapy protocol XELOX + antiangiogenic agent bevaci-
zumab, oncology physician will explain the need of pharmacist and why they must participate in ward 
rounds with physicians and provide their suggestions or recommendations wherever needed. Multipro-
fessional teams are key to a good outcome. As clinical pharmacist have the precise knowledge about anti-
neoplastic drugs and regular interaction with prescribers, they are ideally placed to bridge the gap between 
patients and oncology physicians. Both pharmacist and oncology physicians are learning to form multi-
professional teams.
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S28 – Workshop: Biological therapy – from production and administration to side 
eﬀ ects monitoring
 Damir Vrbanec1,  Robert Šeparović2,  Vesna Pavlica3,  Marko Skelin4
1Department of Oncology, Divison of Medical Oncology, University Hospital Center Zagreb, Croatia 
2Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia 
3Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, 
Zagreb, Croatia 
4Hospital Pharmacy, General Hospital Šibenik, Croatia
Biological drugs belong to new set of drugs developed for various diseases. Biological drugs are pro-
duced in living cells by recombinant technology and are eﬀ ective in stimulating or inhibiting the action of 
natural compounds. Biological drugs diﬀ er from those of chemically synthesized molecules due to their 
origin and their complex structure. An assiesment of immunogenicity is important for biological drugs, in 
line with current guidelines in preclinical and clinical studies and is included in the Pharmacovigilance 
Risk Managment Plan. Therapeutic proteins are produced using genetically modifi ed cell lines or trans-
genic animals. Residual process contamination can be the cause of immunogenicity. Glycosylation or 
pegylation of molecules can mask immunogenic epitopes. Substances which migrate from primary pack-
age can stimulate creation clusters of higher immunogenic potential. The goal of the workshop is to point 
out basics and simple characteristics of biological medicines, a traceability of the applied biological ther-
apy through serialization and writing of protected names of the drug as well as indicating the follow up 
and reporting of side eﬀ ects. Presentation of cases associated with a particular biological therapy will 
point to the critical points of the biological drug tracking chain from receiving drugs in hospital pharmacy, 
to the application of drug and reporting of observed side eﬀ ects.
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S29 – Workshop: Love and sexuality in oncology patients
 Goran Arbanas1,  Jurica Vrbanec2,  Robert Šeparović3,  Olivera Spasovska4
1Psychiatric Hospital Vrapče, Department of Forensic Psychiatry, Zagreb, Croatia 
2Požega Health Center, Croatia 
3Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia 
4Hospital Pharmacy, University Clinic of Abdominal Surgery, Skopje, FYR Macedonia
Oncology patients are facing numerous psychological consequences (hard disease, mourning for lost 
functions, anxiety, depression, fear of the future) among which are very often neglected changes in the 
fi eld of love and sexuality. Because of disease and the treatment (chemotherapy and radiotherapy) there 
are multiple physical changes which may result by damaging the secondary health (e.g. iatrogenic meno-
pause, hormonal imbalance, atrophy of the vaginal mucosa). Some frequent sexual problems are low sex-
ual desire, problems with libido and dyspareunia. However, beside of the physical changes, there are 
psychological changes which can eﬀ ect the sexuality (low self-esteem, changed body image, fear of loos-
ing att raction in partner, and depression) which may have as consequences the avoidance of sex, reduced 
sexual desire and reduced intimacy. Apart from sexuality, there is often loss of intimacy between partners 
and due to reducing communication their love and closeness can be aﬀ ected. Considering patients which 
will never fi rst speak about their sexual and love problems, every expert (doctor, pharmacist) who par-
ticipate in the treatment of oncology patient should learn skills how to communicate with the patient 
about love, sex and methods how to keep their sexual health. This consultation should involve education 
about physiology and psychology of sexuality, using of sexual toys, imagination, stimulation, improving 
communication between partners, stimulating their conversations, exploring and experimenting in 
changed conditions and tighten their relationships, love and closeness.
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S30 - Counseling center for palliative care
 Dahna Arbanas
Public Pharmacy of Karlovac, Croatia
Palliative care is comprehensive (health, psychological, social and spiritual) care with the aim of pro-
viding the neccessary care to patients with unbearable disease that signifi cantly shortens life expectancy. 
The main goal of the palliative care is to reduce pain and unpleasant symptoms of disease so that a patient 
who is at the last stages of the incurable illness or has a chronic severe illness, lived bett er. According to 
defi nition IASP (International Association for the Study of Pain), the pain is unpleasant sensory and emo-
tional experience associated with acute and possible damage. The most commonly used pain measure is 
that one which is defi ned by duration. According to it, pain could be acute, chronic non-malignant and 
chronic malignant. Acute pain is a consequence of tissue injury either by mechanical, thermal or chemical 
means and it lasts relatively short to calm the infl ammation and healing of the injury. Chronic non-malig-
nant pain occurs due to the illness of the musculo-skeletal system, the internal organs or the nervous sys-
tem. Chronic malignant pain is a consequences of tumor tissue injury or diagnostic or therapeutic proce-
dure. Research indicates that every fi fth person suﬀ ers from chronic pain that signifi cantly aﬀ ects the 
quality of life, sleep, work activity and overall health care costs. In order to improve cooperation between 
patients and prevent side eﬀ ects when they use medications, a consulting centres are organised, for 
patients and their family, where they can consult with the expert about analgetics drugs or other drugs 
they use. In pharmacy, through elaborated forms, a pharmacist with patients who suﬀ er from chronic pain 
or a family member, cares for each area related to pain pharmacotherapy (medicines, drug use, disposing 
of medicines, side eﬀ ects, diaries....). Work of pharmacist is introduced to the physician or anesthesiologist 
from a clinic. Showing a few examples of pharmacist’s work in counseling center we will show how to 
communicate with patient or a family member and discover the diﬃ  culties associated with the use of pain 
medicines. Pharmacist with individual approach to the patient, which includes education of the patient or 
family member, can improve treatment and moderate the pain or side eﬀ ects.
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S31 - lmmunotherapy in oncology - interdisciplinary cooperation 
among immunologist, oncologist and pharmacist
 Irena Netikova
Department of Oncology, General University Hospital and First Faculty of Medicine Charles University, 
Prague, Czech Republic
Immune status and immune response becomes an important factor for decision about patient treat-
ment, particularly in time of growing immunotherapy in oncology. Results from Immunoscore programme 
in our department show that patients with stage II colorectal cancer have predominantly a depression in 
cellular immunity. Plasma levels of immunoglobulins were also reduced. Most patients showed some 
clinical symptoms of immunodeﬃ  ciency, such as frequent respiratory tract infections and/or herpetic 
infections. The correlation of neoangiogenic and immunosuppressive factors, as well as the state of anti-
cancer immunity, could help in the future as a prognostic marker and contribute to the selection of tar-
geted immune therapy in patients with colorectal cancer. For this reason ‘Ambulance’ of Immunooncology 
was established in our department, where medical oncologist, immunologist and oncology pharmacist 
cooperate. The aim is to select immunocompromised patients, not only with colorectal cancer, and help to 
stratify them for the most suitable therapy.
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S32 - Novelties in antiemetic supportive therapy
 Vesna Pavlica
Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,, Zagreb, 
Croatia
Nausea and vomiting caused by antitumor drugs and procedures are the most commonly undesir-
able consequences of oncological treatment for the patients. Uncontrolled nausea and vomiting, undoubt-
edly are reducing the quality of life of a patient, also they could lead to the appearance of various compli-
cations such as dehydration, electrolyte imbalance, aspiration pneumonia, esophageal rupture, anorexia, 
malnutrition and worsening of the general condition. Clearly, all of these also signifi cantly aﬀ ects the 
patient’s compliance with the planned oncology therapy, leading to a possible, probable reduction in its 
eﬀ ectiveness. It is estimated that 60-80% of patients treated with chemotherapy are suﬀ ering from nausea 
and vomiting to a certain extent, whereas in patients treated with high doses of cisplatin this percentage is 
as high as 90%. Therefore, the patient’s individual risk and emetogenic potential therapy should be deter-
mined before the therapy begins and on the basis of these two facts, the strategy for the prevention of acute 
and delayed nausea and vomiting. The use of prophylaxis according to the recommendations in the guide-
lines so far allows for the majority of (> 90%) patients receiving high emetogenic chemotherapy to success-
fully prevent nausea and vomiting and thus provide a civilized, quality oncological therapy in the planned 
form, which results in optimal treatment results. Despite the fact that guidelines for the prevention and 
treatment of nausea and vomiting induced by chemotherapy are widely available and based on evidence 
that well-conducted prophylaxis eﬀ ectively improves control of nausea and vomiting in patients, the clin-
ical use of the guidelines remains unacceptably low. Today’s gold standard for the prevention of high and 
medium emetogenic oncological therapies rests on a combination of selective inhibitors of P / neurokinin 
1 (NK1) and 5-HT3 receptor inhibitors. The oral composition of the combination of said drugs, neupitant 
and palonosetron is an optimal formulation from the point of view of the medicine (single oral dosage), 
eﬃ  cacy (potentially more eﬀ ective than a combination of separate medications), and pharmacoeconomic 
aspects (the price is signifi cantly lower than the price of drugs currently on the HZZO Medicines List in 
said indication). The results of the clinical trials gave a clear confi rmation that the oral administration of 
the netupitant / palonosetron in combination with dexamethasone eﬀ ectively prevents acute and delayed 
nausea and vomiting associated with high and moderate emetogenic chemotherapy. The safety profi le of 
the fi xed combination of the netupitant / palonosetron drug is favorable and is no diﬀ erent than expected 
for this drug group, and the frequency of side eﬀ ects is rare and they are mostly of a mild nature.
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S33 - Value-based medicine and pharmacy
 Martina Kranjec Šakić
Hospital Pharmacy, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
The health system of our time is characterized by Evidence-Based Medicine (EBM), patient-centered 
care and cost-eﬀ ectiveness of treatment. EBM involves the conscientious and rational clinical decision 
making on individual patient care based on the best available data from research, clinical experience and 
taking into account patient preferences. This avoids medical errors during treatment and increases the 
quality of patient care. Value-Based Medicine (VBM) is a medicine based on objective value (eg, prolonga-
tion of life and / or quality of life) that is assigned to health interventions using standardized parameters 
that are most commonly used to estimate values and cost-eﬀ ectiveness.
VBM starts with the best evidence-based data and translates them into comprehensible data for value-
based patients and allows clinicians to achieve higher quality of patient care than EBM alone.
VBM is not only cutt ing costs but also improving eﬃ  cacy and cost-eﬀ ectiveness of therapy. Value-
based practice is increasingly important in oncology. Physicians, patients and health-insurances are open 
to innovative oncology treatments, but are all underpressure to choose the treatment that oﬀ ers not only 
the best clinical outcome and the risk and benefi ts ratio, but also the best cost-eﬀ ectiveness for investing in 
the treatment. VBM and EBM are both responses to an increase in the complexity of the healthcare deci-
sion-making process. VBM relies on values in clinical decision making, as EBM relies on facts. The ultimate 
goals of VBM are to raise the quality of the health system and to eﬃ  ciently use the resources within the 
health system. The critical component of understanding the value is measurement, so the parameters for 
estimating the value and the methodology for quantifying these parameters needs to be specifi ed. Oncol-
ogy pharmacists, because of their unique knowledge, qualifi cations, practice, skills and responsibilities 
play an important role in providing oncology patients care. As cancer treatments become more complex, 
more targeted and personalized, the oncological drug market is growing, and with it also the need for 
educated healthcare professionals. Thus, the role of a pharmacist, as a member of the multiprofessional 
team for the care of oncology patients, extends to cover all aspects of that care. Oncology pharmacists 
cooperate with doctors, other healthcare professionals and patients to ensure that prescribed medicines 
contribute to the best possible treatment outcomes for patients.
Pharmaceutical skills certainly aﬀ ect the patient value of treatment through the education of patients, 
their caregivers and other health professionals, assessment of care (including taking medical history and 
therapy adjustment), counseling of patients on proper therapy administration, emphasis on adherence, 
prevention and treatment of side eﬀ ects as well as toxicity of treatment, providing supportive care, moni-
toring of therapy, all with the ultimate goal - improving the quality of life of the patient.
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S34 - Evaluation of pharmacist counseling on oncology patients
 Martina Kranjec Šakić1,  Eugen Javor2
1Hospital Pharmacy, Sestre milosrdnice University Hospital Center, Zagreb, Croatia 
2Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, 
Zagreb, Croatia
More than half of oncology patients occasionally or continuously take diﬀ erent non-prescription 
medications and / or dietary supplements. Apart from the fact that the latt er burdens budget of the patients 
and their families, administration of drug combinations and various dietary supplements without super-
vision by healthcare professionals can lead to unwanted reactions and side eﬀ ects that may delay oncol-
ogy therapy. This brings into question the outcome and success of the oncology treatment and impairs 
quality of patient life. The role of Oncology Pharmacist at Oncology Clinics has not yet been suﬃ  ciently 
recognized in the region. In the Sestre milosrdnice University Hospital Center, in the University Hospital 
for Tumors, the Pharmacist is implemented as an indispensable member of the multiprofesional team, 
where the fi rst infi rmary in Croatia of The Pharmacist counseling on oncology patients was established. In 
order to evaluate the work of an oncological pharmacist, it is necessary to fi nd patt erns on the basis of 
evaluation of such work in countries that already have an established system. The Pharmacist counseling 
of oncology patients is being performed at the University Hospital for Tumors since November 2015. 
Counseling is intended for all oncology patients, their family members, or caregivers who want to be 
 educated on oncology therapy, non-prescription drugs and dietary supplements. Counseling is carried 
out with the aim of: preventing medication errors and drug interactions, adjustment of therapy, patients 
counseling how to properly take their prescribed therapy, patients counseling about potential side eﬀ ects 
of oncological therapy, education on the necessity of strict control of taking dietary supplements. There 
are many papers that have proven that the pharmacist counseling is cost-eﬀ ective. By researching scien-
tifi c and professional literature on the evaluation of counseling by oncology pharmacists, we have come 
up with a form that would serve as a patt ern for developing a national model for evaluation of work. The 
experience of the infi rmary of The Pharmacist counseling on oncology patients of the University Hospital 
for Tumors, Zagreb, and the form of a model for evaluating the work of Oncology Pharmacist in the 
Republic of Croatia will be presented.
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S35 – Workshop: Melanoma – new systemic therapy and its side-eﬀ ects
 Danijela Ledić Drvar1,  Davorin Herceg2,  Irena Netikova Štenglova3
1Division of Dermatology, University Hospital Center Zagreb, Croatia 
2Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia 
3Department of Oncology, General University Hospital and First Faculty of Medicine Charles University, 
Prague, Czech Republic
Melanoma belongs to the group of the most aggressive malignant tumors in humans. It is caused by the 
malignant transformation of melanocytes, melanin-producing cells which is important for the protection of 
skin from UV-mediated damage. Its characteristic is very early metastasis by lymph and hematogenic path-
way, leading to a death. Its incidence, as well as the mortality, has been increasing in the last decades. Unlike 
other tumors, it aﬀ ects a relatively younger population. According to the oﬃ  cial data of the Republic of 
Croatia’s Cancer Registry in 2013, the incidence of melanoma was 12.3 per 100,000 inhabitants. In recent few 
years there has been an evolution, or revolution, in the treatment of patients with advanced stage melanoma. 
The use of new targeted drugs and oncology immunotherapy leads to longer survival of the patients, and 
studies with a combination of these drugs suggest further improvement in the treatment outcomes even at 
this stage of the disease, which had been recently associated with poor prognosis.
At early stage, the best treatment mode represents the surgical removal of the tumor entirely. In the 
treatment of patients with metastatic melanoma, we have several procedures available: surgical treatment of 
metastatic disease is especially recommended if there are solitary (individual) metastases located at the site 
available for surgery; non-surgical treatment of locoregional metastases involves methods such as intratu-
mor interleukin 2 administration; local administration of immunomodulators, imiquimod, and substances 
known to be contact allergens such as dinitrochlorobenzene (DNCB). Electrochemotherapy is a combination 
of intralesional application of cytotoxics (cisplatin or bleomycin), with the use of electrical pulses.
T-VEC is a genetically engineered oncolytic HSV-1 virus. Applies directly to the tumor. It has sys-
temic and local eﬀ ects. It can be combined with immunotherapy.
Systemic treatment of metastatic melanoma: a. targeted therapy includes the application of: 1) BRAF 
inhibitors (vemurafenib, dabrafenib) in patients with BRAF-positive tumor. Prior to the use of this drugs 
patients must be confi rmed to have a BRAF mutation V600 positive tumor; 2) MEK inhibitors (koby-
metinib, trametinib) inhibit the action of mitogen-activating protein kinases; 3) Combination of BRAF and 
MEK inhibitors in clinical studies delay the development of BRAF therapeutic resistance and improve 
overall survival. Today it is considered as a golden standard in the treatment of BRAF positive patients. 
b. oncological immunotherapy includes the application of: 1) Ipilimumab (a monoclonal antibody that 
binds to the CTLA-4 receptor or for one of the control immunological points); 2) anti-PD-1 inhibitors (also 
acting on control immunological points): pembrolizumab and nivolumab; 3) Combination therapy is indi-
cated in patients who can tolerate toxicity, whereas monotherapy is indicated in patients with a poorer 
general condition. The advantage of immunotherapy is that they act on the disease and in BRAF-negative 
tumors, and can also be used after development of resistance to BRAF inhibitors.
Side eﬀ ects of systemic melanoma therapy are: a)side eﬀ ects of combination target therapy are mostly 
mild to moderate. The most severe side eﬀ ects (pyrexia, decreased ejaculation fraction) occur during the fi rst 
weeks of treatment and decrease with time on therapy, and by decrease in dosage of one drug; b) side eﬀ ects 
of oncological immunotherapy are caused by the activation of the immune system. They can aﬀ ect any 
organic system. They appear most commonly in the induction phase but may occur even months after the 
end of the therapy, so it is recommended to monitor the patient up to 5 months after the end of the therapy.
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S36 - Left-right colon cancer and the eﬀ ectiveness of targeted antibodies
 Marko Skelin
Hospital Pharmacy, General Hospital Šibenik, Croatia
Colon carcinoma is one of the most common malignant diseases. Therapeutic protocols used in its 
treatment are based on 5- fl uorouracil in combination with oxaliplatin (adjuvant and metastatic treatment) 
and irinotecan (metastatic treatment). Apart from chemotherapy, for the treatment of metastatic carci-
noma of the colon are used targeted antibodies that can be divided by their basic mechanism of action on 
the inhibitors of the epidermal growth factor receptor (EGFR) and the inhibitors of the vascular endothe-
lial growth factor (anti- VEGF). EGFR inhibitors that are used in the Republic of Croatia are cetuximab and 
panitumumab. These two drugs showed no signifi cant diﬀ erence in their activity when tested in a head to 
head study, and therefore it’s considered that there is no signifi cant diﬀ erence between these two antibod-
ies. Also it is important to highlight that the EGFR inhibitors are in use for the treatment of a wild-type 
RAS colorectal tumor while for the RAS mutated tumors is used anti- VEGF therapy, in particular bevaci-
zumab. Diﬀ erence in eﬀ ectiveness regarding RAS mutation is obtained from randomized controlled stud-
ies (FIRE-3), which showed superiority of cetuximab compared to bevacizumab in a direct comparison. 
The superiority of cetuximab was based on the increase of overall survival compared to bevacizumab. 
However, recently published subanalysis of the two large studies including the FIRE-3, showed that the 
eﬀ ectiveness of targeted antibodies depends of the primary location of the tumor. Tumors of the right side 
of colon have poorer survival compared to the tumors of the left side of colon and also had an unexpected 
diﬀ erence in the eﬃ  cacy of targeted antibodies. Bevacizumab showed a similar eﬃ  cacy regardless the side 
of the colon, while cetuximab surprisingly showed the lack of eﬃ  cacy compared to bevacizumab in a wild-
type RAS tumor of the right side of the colon. The aim of this lecture will be to present the latest fi ndings 
on the eﬀ ectiveness of targeted antibodies in patients with metastatic carcinoma of the colon, depending 
on the primary location of the tumor.
Lib Oncol. 2017;45(Suppl. 1), 1–42
40
S37 - Central Preparation of Antineoplastic Drugs: Practice and Experiences
 Lidija Gajski1,  Olivera Spasovska2,  D. Aleksić3,  Vesna Pavlica4
1Hospital Pharmacy, University Hospital Center Zagreb, Croatia 
2 Hospital Pharmacy, University Clinic for Abdominal Surgery, Skopje, FYR Macedonia 
3Hospital Pharmacy, Clinical University Center Sarajevo, Bosnia and Herzegowina 
4Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, 
Zagreb, Croatia
Medical errors related to antineoplastic drugs are subject to multilple researches, whereas in the 
Republic of Croatia, that is still a subject of discussion. Insuﬃ  cient information which would serve as a 
basis for a conclusion about the extent medical error is present in Croatian hospital system.
By supervising prescribed drugs, dosages, solutions, and correct preparation and instructions for 
accurate application, oncology pharmacists can to a great extent contribute to a safe application of drugs 
in hospitals, reducing, by doing so, the margin of medication error.
Drugs that make part of the chemotherapy protocol of a patient, accompanied or not by biological 
therapy, get prepared in accordance with instructions from the Summaries of Product Characteristics 
(SPC). Due to individual diﬀ erences between patients and the need to adjust these protocols, other refer-
ential data from literature are also used. Antineoplastic drugs are prepared in microbiologically validated 
space by manipulation in aseptic conditions. Sterile state of the prepared drug is of outstanding impor-
tance, because the immune system of oncology patients is often compromised due to side eﬀ ects which are 
the consequence of the therapy itself.
By organizing the entire procedure, from recieving and control of the request for chemotherapy, the 
pre-preparation procedure, the preparation, visual control of ready preparations, the packaging of chemo-
therapy and its application at wards, an entire system of multiple controls prior to application is estab-
lished. In this way, we att empt to reduce the occurence of undesired events which could threaten the 
health of the patient and increase treatment costs.
In everyday work the most used are the world and the national guidelines as well as QUAPOS - Qual-
ity Standard for the Oncology Pharmacy Service edited by ESOP ( European Society of Oncology Phar-
macy).
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Oncology Pharmacy is a specialized branch of pharmacy, which includes a pharmacist’s activity and 
service, which complete the personalized treatment of the patient. That presupposes a rational and opti-
mized use of drugs, and activities complementary to those of other medical professionals.
A pharmacist will take part in the work of a multiprofessional health care team focusing on oncology 
pharmacy and oncology pharmacy practice. Oncology pharmacy practice includes activities such as han-
dling antineoplastic drugs and counselling of oncology patients.
In order for an oncology pharmacist to take part in professional counselling in everyday work, a spe-
cial education and training are required. That is why the graduate course at the Centre for Applied Phar-
macy performs education and professional training as a part of the subject entitled ‘Pharmaceutical Care’. 
Students acquire knowledge relative to pharmaceutical care for an oncology patient. A total of 13 periods 
of education in Oncology Pharmacy take place as a part of a Specialized Course in Clinical Pharmacy. The 
lecturer is Damir Vrbanec, MD PhD, with support of Robert Šeparović, MD PhD, and Vesna Pavlica, 
MPharm PhD, Borislav Belev, MD PhD, and Natalija Dedic Plavetic, MD PhD. As a part of subject ‘Phar-
macotherapy in Clinical Oncology’, specializing interns spend a month in the Medical Oncology Ward, 
Department of Medical Oncology and Radiotherapy of the University Hospital for Tumors, Sestre milosrd-
nice University Hospital Center, menthored by Robert Šeparović, MD PhD. Practical work in Oncology 
Pharmacy takes place in the pharmacy of the same clinic, for two months, supervised by Vesna Pavlica, 
MPharm PhD, and Martina Kranjec Šakić, MPharm.
Likewise, a subject of Pharmacotherapy of Malignant Diseases (15 periods) has been introduced at 
the fi fth year of the Pharmacy Course of the Pharmaceutical - Biochemical Faculty of the Unversity of 
Zagreb.
The heads in this subject are Vesna Bačić Vrca, MPharm PhD, and Damir Vrbanec, MD PhD, whereas 
Robert Šeparović, MD PhD, and Vesna Pavlica, MPharm PhD, are the collaborators.
The book authored by Semir Bešlija, MD PhD, and Damir Vrbanec, MD PhD, entitled ‘Medical Oncol-
ogy’ is the most useful tool in our everyday work.
The Center for Applied Pharmacy of the Pharmaceutical Biochemical Faculty of the University of 
Zagreb organizes the student internship and Professional Training for Pharmacists, a total of 720 hours. 
The programme is based on the Croatian Pharmaceutical Competency Framework and contains a list of 
activities to be undertaken for achieving the expected competencies for student interns. There is a special 
programme within it for the students who want to spend this part at the University Hospital for Tumors, 
with heads being Vesna Pavlica MPharm PhD and Robert Šeparović MD PhD. These are the issues a spe-
cial emphasis is placed on: safe handling of antineoplastic drugs, optimization of therapy by providing 
pharmacists’ care to the oncology patient and side eﬀ ects.
Everyday work at the University Hospital for Tumours takes place at the Medical Oncology Ward, at 
the outpatients clinic, day hospital and at the pharmacy. Education also takes place as a part of pharma-
ceutical counselling of oncology patients concerning the application and coordination of drugs and nutri-
tion supplements.
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Patient counselling is intended for all oncology patients and their family members who wish to get 
educated on the over the counter drugs, herbal drugs and nutrition supplements. Such counselling is per-
formed in order to prevent medical errors and drug interaction, to have therapy harmonization, perform 
patient counselling on therapy adherence and educate on the need for strict control of nutrition supple-
ments. Combining can lead to undesired side eﬀ ects, which can result in postponing oﬃ  cial therapy, thus 
jeopardizing the outcome and success of patient treatment and interfereing with the patients’ quality of 
life. The expert team for quality counselling needs to have insight into the oﬃ  cially prescribed therapy 
(medical documentation) and other drugs prescribed by a GP. By talking to the patient the team members 
will learn about all over the counter drugs and nutrition supplement their patients take. Based on the 
information thus obtained, personal patient training will take place. Counselling is performed by a team 
of top-notch professionals: Vesna Pavlica, MPharm PhD, Robert Šeparović, MD PhD, Eugen Javor, 
MPharm, Martina Kranjec Šakić, MPharm, Dahna Arbanas MPharm, and Marko Skelin, MPharm. This 
kind of education, along with the direct contact with the patient, is the best for helping train the best future 
experts in oncology pharmacy, with objective of improving treatment outcome, quality of life of the 
patient, adherence and pharmacoeconomical saving.
